Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Long-Term Debt Issuances for 5 consecutive years, with -$575.0 million as the latest value for Q3 2025.

  • Quarterly Long-Term Debt Issuances fell 227.78% to -$575.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Jun 2025, changed N/A year-over-year, with the annual reading at $450.0 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Issuances hit -$575.0 million in Q3 2025 for BridgeBio Pharma, down from $575.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $747.5 million in Q1 2021 to a low of -$722.5 million in Q3 2021.
  • Historically, Long-Term Debt Issuances has averaged $113.3 million across 3 years, with a median of $440.6 million in 2021.
  • Biggest YoY gain for Long-Term Debt Issuances was 227.78% in 2025; the steepest drop was 227.78% in 2025.
  • Year by year, Long-Term Debt Issuances stood at $431.3 million in 2021, then grew by 4.34% to $450.0 million in 2024, then tumbled by 227.78% to -$575.0 million in 2025.
  • Business Quant data shows Long-Term Debt Issuances for BBIO at -$575.0 million in Q3 2025, $575.0 million in Q2 2025, and $450.0 million in Q3 2024.